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We sought to describe the epidemiology of Clostridium difﬁcile infection (CDI) among adult recipients of
autologous hematopoietic stem cell transplantation (auto-HSCT) within the ﬁrst year after HSCT in centers
with variable epidemiology of hypertoxigenic strains. A multicenter, retrospective nested case-control study
was conducted among 873 auto-HSCT recipients at Johns Hopkins Hospital (JHH) and Hôpital Maisonneuve-
Rosemont (HMR) between January 2003 and December 2008. Despite center differences in the prevalence of
NAP-1 strains during the study period (21% to 43% at JHH versus 80% to 84% in HMR), the 1-year incidence of
CDI was similar in the 2 hospitals (6.2% at JHH versus 5.7% at HMR). The median time to infection was 11 days
(interquartile range, 1 to 27 days). In case-control analyses, grade 2 mucositis (odds ratio [OR], 3.00; P ¼ .02)
and receipt of a fourth-generation cephalosporin (OR, 2.76; P ¼ .04) were identiﬁed as predictors for CDI.
Mucositis was the strongest predictor of risk for CDI in multivariate analysis (adjusted OR, 2.77; P ¼ .03). CDI is
a common and early complication of auto-HSCT. Treatment-related gastrointestinal mucosal damage, along
with the potentially modiﬁable risk of antimicrobial exposure, inﬂuence the risk for CDI early after auto-HSCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION of patients in centers with variable high and low endemicity
Clostridium difﬁcile is a Gram-positive bacterium respon-
sible for >500,000 cases of infectious diarrhea and >14,000
deaths in the United States annually [1-4]. It is considered
the leading cause of infectious diarrhea among hospitalized
patients and is a major concern in immunosuppressed indi-
viduals. Escalating rates of infection worldwide, coupled
with the emergence of an epidemic hypertoxigenic strain of
C difﬁcile known as NAP-1, have heightened concerns about
the impact of this infection on hospitalized patients [5,6].
Hematopoietic stem cell transplantation (HSCT) recipients
represent one of the most immunologically vulnerable
populations and may be at a particularly high risk for Clos-
tridium difﬁcile infection (CDI) given underlying immuno-
deﬁciencies, long hospitalizations, receipt of broad-spectrum
antibiotics, and chemotherapy-related disruption of enteric
mucosal barriers [7]. Previous studies have identiﬁed CDI as
a common early complication after autologous HSCT (auto-
HSCT), but little is known about risks [8-10]. The present
study was performed to examine the contemporary epide-
miology of CDI and to assess risk factors and clinical
outcomes among recipients of auto-HSCT, evaluating cohortsedgments on page 1507.
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METHODS
Patient Population and Data Collection
This study was approved by the Johns Hopkins University School of
Medicine and the Hôpital Maisonneuve-Rosemont Institutional Review
Boards. Subjects consisted of all adult patients who underwent auto-HSCTat
Johns Hopkins Hospital (JHH) in Baltimore or Hôpital Maisonneuve-
Rosemont (HMR) in Montreal between January 1, 2003, and December 31,
2008. During the study period, 487 auto-HSCTs were performed at JHH and
386 auto-HSCTs were performed at HMR. Patient-level data were retro-
spectively collected frommedical charts at individual sites and pooled using
a centralized REDCap electronic data capture system hosted by JHH [11].
Data collected included demographic information, underlying hemato-
logic malignancy, number of chemotherapy regimens before the current
HSCT, admission and discharge dates, history of previous transplantation,
conditioning regimen, stem cell source, and receipt of rituximab, corticoste-
roids, or protonpump inhibitors. Antimicrobial exposurewas recordedwithin
the 30 days before HSCT (day30 through day8) and during the early post-
transplantation period (day 7 through day þ40) for all patients. Trans-
plantation complications, including mucositis, duration of neutropenia, and
infectious complications occurring in the ﬁrst 40 days post-HSCT were
recorded. In the patients with CDI, charts were reviewed for clinical features
associated with CDI, including fever and duration of fever. Laboratory
parameters included total WBC count, absolute neutrophil count, absolute
lymphocyte count, absolutemonocyte count, and creatinine values during the
week before and on the day of CDI and albumin level on the day of CDI. Charts
were reviewed for start and stop dates of CDI treatments, including oral and
i.v. metronidazole, oral vancomycin, and other potentially confounding
therapies (eg, i.v. immune globulin, nitazoxanide, rifaxamin, probiotics).
Deﬁnitions
CDI-speciﬁc. Both centers deﬁned CDI as a clinical history compatible
with CDI, diarrheal stool, and a positive test for toxin-producing C difﬁcileTransplantation.
Figure 1. One-year incidence of CDI in auto-HSCT recipients, stratiﬁed by
center. Overall CDI incidence did not vary signiﬁcantly between the 2 centers
from 2003 through 2008. Infections were recorded from 7 days before auto-
HSCT through 1 year after auto-HSCT. Patients undergoing more than 1
auto-HSCT were included once per calendar year.
C.D. Alonso et al. / Biol Blood Marrow Transplant 19 (2013) 1502e1508 1503within the ﬁrst year after HSCT. Both centers used standardized
infection and transplantation deﬁnitions [8]. Because the frequency and
severity of stool output are difﬁcult to determine retrospectively
from physician and nursing notes, these variables were not included in our
case deﬁnition. Recurrent CDI was deﬁned as that occurring after
completion of a course of metronidazole or vancomycin for an initial
episode.
High-risk antibiotics. Anti-pseudomonal penicillins, fourth-generation
cephalosporins, carbapenems, absorbable ﬂuoroquinolones, and clindamy-
cin were considered high-risk CDI antibiotics [12,13].
Transplant-speciﬁc. At JHH, patients who received high-dose chemo-
therapy with cyclophosphamide without stem cell rescue for severe
autoimmune disease were classiﬁed as having undergone auto-
HSCT [14,15]. Engraftment was deﬁned as 3 days with an absolute
neutrophil count >500 cells/mL, with the ﬁrst day recorded as the day of
engraftment. Transplantation-related mucositis was deﬁned according to
established guidelines under the National Cancer Institute’s Common
Terminology Criteria for Adverse Events v3.0 [16]. Infections were
categorized as bacterial, viral, or fungal based on symptoms, microbio-
logical data, clinician assessments, and response to speciﬁc treatments.
Fungal infections were deﬁned as possible, probable, or proven based on
established guidelines [17]. Fever was deﬁned as any temperature38.0C
at the time of CDI. Neutropenia, lymphopenia, and monocytopenia
were deﬁned as <500, <300, and <300 cells/mL, respectively, on
3 consecutive days concurrent with CDI. Hypoalbuminemiawas deﬁned as
a serum albumin level <2.5 mg/dL. Acute renal failure was deﬁned as a
creatinine level >50% of the baseline level within the 7 days
before CDI, using the lowest creatinine value in that period as the refer-
ence value.
Laboratory Methods
At JHH, between October 2002 and May 2004, C difﬁcile toxin was
assessed using the cell culture cytotoxin neutralization assay (CCNA) [18].
Between June 2004 and June 2009, an initial screen was performed for
C difﬁcile common antigen (glutamate dehydrogenase) using a commer-
cial antigen immunoassay (C. DIFF CHEK-60; TechLab, Blacksburg, VA),
and positive tests were conﬁrmed with a CCNA. Between June 2009
and December 2009, an initial screen for common antigen was per-
formed, followed by conﬁrmatory testing for toxin using quantitative PCR
for the toxin B gene (BD GeneOhm Cdiff assay; BD Diagnostics, San Diego,
California). The NAP-1 strain was detected in 21% of convenience samples
among randomly chosen hospital isolates in 2005 and in 43% of these
samples in 2008 [19].
At HMR, between October 2002 and June 2005, C difﬁcile toxin was
assessed using the CCNA. Between June 2005 and January 2010, C difﬁcile
toxin was assessed in hospitalized patients using a commercial immuno-
assay (ImmunoCard C. difﬁcile A&B; Meridian Biosciences, Cincinnati, OH),
whereas CCNAwas still used for outpatients. The NAP-1 strain was detected
in 140 of 175 samples (80%) of hospital isolates in 2003 to 2004 [6]. Between
2005 and 2011, as part of a provincial surveillance program, 7 to 15 strains
isolated from a yearly convenience sample were typed. Overall, the NAP-1
strain was detected in 50 of 59 samples (84%).
Statistical Analysis
In the population of auto-HSCT recipients from 2003 through 2008, the
cumulative incidence of CDI was calculated by dividing the number of
patients who developed CDI within 1 year of transplantation by the total
number of auto-HSCTs performed in each calendar year. For patients who
underwent more than 1 auto-HSCT in a calendar year, the ﬁrst trans-
plantation was used. A test for linear trend was used to compare differences
in rate of infection by year of transplantation. Two-sided P values of < .05
were considered to indicate statistical signiﬁcance.
In a case-control study evaluating risk factors for CDI, controls were
matched to cases at a 2:1 ratio by date of auto-HSCT using cumulative
incidence sampling based on an algorithm programmed in Stata version 11
(StataCorp, College Station, TX). Three patients had only 1 appropriate
control available for analysis; our methodology accounted for this differ-
ence. First, univariate analyses were performed using logistic regression to
evaluate the effect of recipient-related factors, transplant characteristics,
transplantation complications, and antimicrobial exposure on the risk for
CDI alone. Then a multivariate model was built from variables identiﬁed as
statistically signiﬁcant in univariate analyses (P  .20), considering biologic
plausibility and potential confounders. Backward elimination was used to
reﬁne the model and increase the precision of effect estimates, again with
a threshold of P < .20 for inclusion in the ﬁnal model [20]. Conditional
logistic regression was used to account for the matched study design. All
statistical analyses were performed using SAS version 9.2 (SAS Institute,
Cary, NC).RESULTS
Rates
Combining data from both centers, a total of 53 cases of
CDI were identiﬁed among 873 auto-HSCTs (6.1%) performed
during the study period. Overall, the 1-year cumulative
incidence of CDI was 6.2% at JHH (30 infections among 487
auto-HSCTs) and 5.7% at HMR (23 infections among 386
auto-HSCTs). A marginal decline in the CDI rate in auto-HSCT
recipients was seen at both centers in 2008 compared with
2007 (Figure 1).
Timing
The median time to CDI in the study cohort was 11 days
(interquartile range [IQR], 1 to 27 days). The median time to
infection was 18 days (IQR, 10 to 35 days) at HMR and
6.5 days (IQR, 1 to 21 days) at JHH (P ¼ .10). When patients
who received high-dose cyclophosphamide as an auto-
equivalent regimen were excluded from the analysis, the
median time to infection at JHH was 4.5 days (IQR, 2 to
21 days; P ¼ .01 versus HMR). Of the 53 cases, 43 (81%)
occurred within the ﬁrst 30 days after transplantation.
Clinical Characteristics/Antimicrobial Exposure
Each of the 53 auto-HSCT recipients was matched with
a control (Table 1). The median age of cases was 56 years
(range, 46 to 62 years), with a greater proportion of case
patients over age 50 compared with controls (67.9% versus
55.9%; P ¼ .14). In the majority of patients, the underlying
hematologic malignancy was lymphoma or multiple
myeloma (51.0% and 32.9%, respectively). The majority of
case and control patients had received between 1 and 3
regimens of chemotherapy before the current auto-HSCT
(73.6% versus 81.4%; P ¼ .90), with more cases than
controls receiving more than 3 previous chemotherapy
regimens (15.1% versus 6.9%; P ¼ .26). Antimicrobial use
within 30 days before HSCT, stem cell source, use of proton
pump inhibitors, and duration of hospitalization for HSCT
were similar in cases and controls. Eighteen case patients
(34.0%) and 26 control patients (25.5%) received rituximab
during the course of transplantation (P ¼ .17). When strati-
ﬁed by severity of mucositis, case patients were more likely
to have experienced grade 2 mucositis during the course of
transplantation (35.8% versus 19.6%; P ¼ .02).
Table 1
Demographic and Clinical Characteristics of 53 auto-HSCT Recipients with CDI and 102 Matched Controls, 2003-2008
Variables Cases, n (%) Controls, n (%) Total, n (%) P Value
Number of patients 53 102 155
Center
JHH 30 (56.6) 59 (57.8) 89 (57.4) .88
HMR 23 (43.4) 43 (42.2) 66 (42.6)
Recipient-related factors
Age at HSCT, y, median (IQR) 56 (46-62) 52.5 (42-59) 54 (43-60) .05
Age 18-49 y at HSCT, n (%) 17 (32.1) 45 (44.1) 62 (40.0)
Age 50 þ y at HSCT, n (%) 36 (67.9) 57 (55.9) 93 (60.0) .14
Male sex, n (%) 35 (66.0) 53 (52.0) 88 (56.8) .11
Hematologic malignancy, n (%)
Acute leukemias* 3 (5.7) 4 (3.9) 7 (4.5) .61
Chronic leukemiasy 0 (0.0) 1 (1.0) 1 (0.6) .99
Multiple myeloma 17 (32.1) 34 (33.3) 51 (32.9) .89
Lymphoma 28 (52.8) 51 (50.0) 79 (51.0) .74
Other malignanciesz 1 (1.9) 7 (6.9) 8 (5.2) .21
Other conditions, n (%)x 4 (7.5) 5 (4.9) 9 (5.8) .43
Previous chemotherapy regimens, n (%)
None 6 (11.3) 12 (11.8) 18 (11.6)
1-3 39 (73.6) 83 (81.4) 122 (78.7) .90
>3 8 (15.1) 7 (6.9) 15 (9.7) .26
Use of antibiotics within 30 days of HSCT, n (%) 18 (34.0) 40 (39.2) 58 (37.4) .38
Transplantation-related characteristics
Previous HSCT, n (%) 0 (0.0) 1 (1.0) 1 (0.6) .99
Stem cell source, n (%)
BM 3 (5.7) 4 (3.9) 7 (4.5) .60
Peripheral blood 42 (79.2) 84 (82.4) 126 (81.3) .40
Receipt of high-dose cyclophosphamide, n (%) 8 (15.1) 14 (13.7) 22 (14.2) .72
Conditioning regimen, n (%)
Nonemelphalan-containing 35 (66.0) 60 (58.8) 95 (61.3)
Melphalan-containingk 18 (34.0) 42 (41.2) 60 (38.7) .14
Receipt of rituximab, n (%) 18 (34.0) 26 (25.5) 44 (28.4) .17
Receipt of steroids (days 0 to þ40), n (%){ 38 (71.7) 74 (72.5) 112 (72.3) .64
Receipt of proton pump inhibitors (days 0 to þ40), n (%) 38 (71.7) 77 (75.5) 115 (74.2) .49
Duration of hospitalization for HSCT, d, median (IQR) 18 (0-22) 19 (6-23) 19 (4-23)
<20 31 (58.5) 52 (51.0) 83 (53.5)
20 22 (41.5) 50 (49.0) 72 (46.5) .32
Receipt of high-risk C difﬁcile antibiotic (days 7 to þ40), n (%)# 41 (77.4) 73 (71.6) 114 (73.5) .46
Transplantation-related complications
Mucositis, n (%)
None or grade 1 34 (64.2) 77 (75.5) 80 (51.6)
Grade 2, 3, or 4 19 (35.8) 20 (19.6) 31 (20.0) .02
Missing grade 0 (0.0) 5 (4.9) 5 (3.2)
Time to engraftment, days, median 11 11 .83
Early infection (any), day 0 to day þ40, n (%) 26 (49.1) 41 (40.2) 67 (43.2) .37
* Including acute myelogenous leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia.
y Including chronic myelogenous leukemia and chronic lymphocytic leukemia.
z The most common other malignancies included aplastic anemia (n ¼ 5), osteosarcoma (n ¼ 1), desmoplastic round cell tumor (n ¼ 1), and lymphoma plus
myeloma (n ¼ 1).
x The most common other conditions included myasthenia gravis, systemic lupus erythematosis, and multiple sclerosis.
k Patients receiving melphalan-containing regimens received 120 mg/m2 or 200 mg/m2, depending on regimen, or the BEAM regimen (n ¼ 11).
{ Two patients had missing data.
# High-risk antibiotic use included receipt of antipseudomonal penicillin, a fourth-generation cephalosporin, carbapenem, an absorbable ﬂuroquinolone, or
clindamycin.
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otics during the course of transplantation, with slightly
more case patients (28.3%) receiving courses of >2 weeks
duration compared with controls (20.6%) (Table 2). Case
patients were more likely to have received high-risk anti-
biotics (77.4%) during the transplant compared with
controls (71.6%); however this ﬁnding was not statistically
signiﬁcant in the univariate analysis (P ¼ .46). When eval-
uated by speciﬁc class of high-risk antibiotic, case patients
were more likely to have been exposed to a fourth-
generation cephalosporin (32.1% versus 19.6%; P ¼ .04),
with evidence suggesting an association with exposure to
an absorbable ﬂuroquinolone (47.2% versus 36.3%; P ¼ .17).
The ﬁnal multivariate model identiﬁed grade 2 mucositis
as the strongest predictor of risk for CDI (OR, 2.77; 95% CI,
1.08 to 7.09; P ¼ .03), adjusting for age, receipt ofﬂuroquinolone, and receipt of melphalan (Table 3). Male
sex, receipt of rituximab, and receipt of a fourth-generation
cephalosporin were considered but excluded from the ﬁnal
model in the backward elimination approach.
Clinical Features of CDI
Clinical characteristics of the patients with CDI are
summarized in Table 4. Fever was present in 20 of the 53
patients (37.7%), persisting for 2 days on average (range, 1 to
3 days). Traditional markers of severe CDI, including leuko-
cytosis >20,000 cells/mm3 (1.9%), hypoalbuminemia (0%),
and the need for colectomy (0%), were rare. In contrast,
neutropenia (23.1%), lymphopenia (48.1%), and mono-
cytopenia (30.8%) were common. Monotherapy with oral
metronidazole was the most commonly prescribed treat-
ment (61.5%), followed by combination therapy with oral or
Table 2
Antibiotic Utilization among 53 auto-HSCT Recipients with CDI and 102 Matched Controls
Variables Cases, n (%) Controls, n (%) Total, n (%) P Value
Receipt of antibiotics within 30 days of HSCT, n (%) 18 (34.0) 40 (39.2) 58 (37.4) .38
Receipt of antibiotics during course of HSCT, n (%)* 53 (100.0) 102 (100.0) 155 (100.0)
Receipt of high-risk C difﬁcile antibiotic, n (%)y 41 (77.4) 73 (71.6) 114 (73.5) .46
None 12 (22.6) 29 (28.4) 41 (26.5)
Duration <2 weeks 26 (49.1) 52 (51.0) 78 (50.3) .62
Duration 2 weeks 15 (28.3) 21 (20.6) 36 (23.2) .24
Speciﬁc class of high-risk C. difﬁcile antibiotic, n (%)
Antipseudomonal penicillin 12 (22.6) 32 (31.4) 44 (28.4) .28
Fourth-generation cephalosporin 17 (32.1) 20 (19.6) 37 (23.9) .04
Carbapenem 14 (26.4) 27 (26.5) 41 (26.5) .83
Absorbable ﬂuoroquinolone 25 (47.2) 37 (36.3) 62 (40.0) .17
Clindamycin 1 (1.9) 1 (1.0) 2 (1.3) .62
* Data on antibiotics collected from day 7 to day þ40.
y High-risk antibiotic use includes receipt of antipseudomonal penicillin, a fourth-generation cephalosporin, carbapenem, an absorbable ﬂuroquinolone, or
clindamycin.
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treatment was not identiﬁed in 1 patient, and 3 patients did
not receive CDI-appropriate therapy (1 at HMR and 2 at JHH).
The reasons for lack of therapy included late results of toxin
testing and resolved diarrhea in 1 patient and lack of clinical
documentation of treatment and/or outcomes for CDI in the
medical record in 2 patients.
Outcomes
Recurrent disease was noted in 8 patients (15.4%), with
a median time to recurrence of 28 days after the initial
episode. Only 1 patient had multiple recurrences. Among the
patients with recurrent disease, 50% (n ¼ 4) had received
rituximab during the course of transplantation. The small
number of patients with recurrent disease limited further
risk analysis, however. The 30-day all-causemortality was 0%
in cases (0 of 53) and 2% in controls (2 of 102). The 60-day all-
cause mortality was slightly higher in controls (1 of 53 cases
versus 6 of 102 controls; P ¼ .88).Table 3
Risk Factor Analysis for CDI among auto-HSCT Recipients and Matched Controls, 2
Variable Controls,
n (%)
Cases,
n (%)
Total,
n (%)
M
U
O
Number of patients 102 53 155
Center
Baltimore 59 (57.8) 30 (56.6) 89 (57.4) 0
Montreal 43 (42.2) 23 (43.4) 66 (42.6) 1
Age at transplant, y,
median (IQR)
52.5 (42-59) 56 (46-62) 54 (43-60) -
Age 18-49 y 45 (44.1) 17 (32.1) 62 (40.0) 1
Age 50 þ y 57 (55.9) 36 (67.9) 93 (60.0) 1
Male sex 53 (52.0) 35 (66.0) 88 (56.8) 1
Receipt of a melphalan-
containing regimen
42 (41.2) 18 (34.0) 60 (38.7) 0
Receipt of rituximab 26 (25.5) 18 (34.0) 44 (28.4) 1
Mucositis
None or grade 1 77 (75.5) 34 (64.2) 111 (71.6) 1
Grade 2, 3, or 4 20 (19.6) 19 (35.8) 39 (25.2) 3
Missing grade 5 (4.9) 0 (0.0) 5 (3.2) E
Receipt of a fourth-
generation cephalosporin
20 (19.6) 17 (32.1) 37 (23.9) 2
Receipt of an absorbable
ﬂuoroquinolone
37 (36.3) 25 (47.2) 62 (40.0) 1DISCUSSION
In this combined multicenter study of 873 auto-HSCTs at
2 large transplantation centers, the cumulative incidence of
C difﬁcile infection was 6.1% in the ﬁrst year after auto-HSCT,
with the majority of infections clustered within the ﬁrst
20 days after transplantation. However, these rates may
underestimate the true burden of this disease beyond the 1-
month period, when many patients return to their primary
oncologist for longitudinal care. Chemotherapy-associated
mucositis was associated with the greatest risk for CDI,
with a >2-fold increased risk in patients with grade 2
mucositis by the National Cancer Institute’s Common
Terminology Criteria for Adverse Events v3.0. Host factors, in
addition to traditional risks for CDI (including antimicrobial
exposure), appear to play a vital role in the infectious risk in
this population.
We compared CDI cases among auto-HSCT recipients at
institutions with signiﬁcantly different rates of NAP-1
strains. Despite higher rates of NAP-1 circulating in the003-2008
atched OR,
nadjusted
Matched OR, Adjusted
for All Candidate
Predictors
Matched OR, Adjusted
for Candidate
Predictors after
Backward Elimination
R (95% CI) P OR (95% CI) P OR (95% CI) P
.95 (0.49-1.86) .88 NA NA NA NA
.00 (reference) - NA NA
-
.00 (reference) - 1.00 (reference) 1.00 (reference)
.78 (0.83-3.84) .14 1.81 (0.77-4.26) .17 1.90 (0.82-4.39) .13
.77 (0.88-3.57) .11 1.20 (0.55-2.64) .65
.40 (0.12-1.35) .14 0.44 (0.10-1.94) .28 0.34 (0.09-1.34) .12
.89 (0.77-4.66) .17 1.34 (0.45-3.95) .60
.00 (reference) 1.00 (reference) 1.00 (reference)
.00 (1.19-7.59) .02 2.39 (0.91-6.29) .08 2.77 (1.08-7.09) .03
xcluded
.76 (1.03-7.42) .04 1.83 (0.62-5.43) .28
.66 (0.81-3.41) .17 1.77 (0.81-3.86) .15 1.83 (0.85-3.94) .12
Table 4
Clinical Characteristics of 53 auto-HSCT Recipients with CDI
Variable Value
Clinical and laboratory features
Previous history of CDI, n (%) 1 (1.9)
Temperature >38.0C, n (%) 20 (37.7)
Duration of fever, days, median (IQR) 2 (1-3)
Laboratory parameters
WBC count, median (IQR) 4700 (1380-8300)
Neutropenia, n (%) 12 (23.1)
Absolute neutrophil count, cells/mL,
median (IQR)
3700 (545-6730)
Lymphopenia, n (%) 25 (48.1)
Absolute lymphocyte count, cells/mL,
median, IQR)
260 (100-800)
Monocytopenia, n (%) 16 (30.8)
Absolute monocyte count, cells/mL,
median (IQR)
345 (40-900)
Serum creatinine level >50% baseline
value, n (%)
2 (6.1)
Serum albumin, mg/dL, median (IQR) 3.6 (3.3-3.9)
Serum albumin <2.5 mg/dL, n (%) 0 (0)
CDI treatment modality, n (%)
Receipt of CDI treatment 49 (94.2)
Regimens containing metronidazole only
Metronidazole, oral 32 (61.5)
Metronidazole, i.v. 0 (0)
Metronidazole, oral and i.v. 4 (7.7)
Vancomycin-containing regimens
Vancomycin, oral and metronidazole, oral 0 (0)
Vancomycin, oral 5 (9.6)
Vancomycin, oral and metronidazole,
oral and i.v.
7 (13.5)
Duration of CDI treatment, days, median (IQR) 14 (11-16)
Outcome information
Recurrent disease, n (%) 8 (15.4)
Time to recurrence from initial episode, days,
median (IQR)
28 (15-80)
More than 1 recurrence, n (%) 1 (12.5)
Need for colectomy, n (%) 0 (0)
Need for mechanical ventilation, n (%) 1 (1.9)
Percentages might not sum to 100% owing to missing data.
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marginally lower overall at HMR, suggesting that other
factors (ie, differences in transplant populations, testing
methods, or infection control practices) might have played a
more inﬂuential role. Furthermore, we found a difference in
the timing of disease between the 2 centers, with more
earlier disease observed at JHH compared with HMR.
It is possible that variations in pretransplantation coloniza-
tion rates between the centers account for some of the
observed differences; this remains to be evaluated in
prospective studies.
The current body of literature suggests that CDI rates in
patients with cancer aremore than double those reported for
all hospitalized patients in the United States [21]. Among
auto-HSCT recipients, these rates have ranged between 5%
and 15% [9,10,22-24], with most infections occurring within
the ﬁrst 30 days after transplantation [9,10]. In a study that
evaluated infectious complications in the ﬁrst year after
auto-HSCT for breast cancer, CDI was the second most
common infection after bacteremia [25]. Our data comple-
ment and extend these ﬁndings, with a 6.1% incidence of CDI
in the year after transplantation and very early timing of
infection in most cases. Compared with recipients of allo-
geneic HSCT, who may have a longer at-risk period owing to
delayed immune function and graft-versus-host disease,
the timing of disease in auto-HSCT recipients appears to
be correlated with maximum mucosal damage fromchemotherapeutic agents, with declining rates after the
period of cellular engraftment. The very early timing of
disease has been observed in other transplantation pop-
ulations [26] and may be associated with increased risk for
disease owing to colonization at time of admission for
transplantation as a consequence of previous chemotherapy
for the underlying malignancy [27].
To our knowledge, this study is the ﬁrst to provide
a detailed risk factor assessment for CDI in this immuno-
suppressed population. Previous studies have implicated
traditional risk factors, such as antimicrobial exposures [22]
and chemotherapeutic agents [28], but have been limited
by small numbers of subjects and an inability to control for
confounding factors. Our univariate analysis identiﬁed some
important trends, including an increased risk for CDI in older
patients, male patients, patients who had received rituximab
during transplantation, and patients with grade 2 muco-
sitis. Antibiotic exposure, particularly receipt of a fourth-
generation cephalosporin or an absorbable ﬂuoroquinolone,
appeared to provide additional risk in univariate analysis. In
multivariate analysis, grade 2 mucositis appeared to be the
factormost signiﬁcantly associatedwith risk for CDI. This risk
factor seemed to play a more important role than antimi-
crobial exposure, which did not reach statistical signiﬁcance
in the model. We offer 2 possible explanations for this
ﬁnding. First, patients with severe mucositis may be more
likely to be tested for CDI, resulting in a possible sampling
bias. Unfortunately, the frequency of negative C difﬁcile
testing was not noted in the control patients, which might
have helped answer this question. Alternatively, mucosal
damage from chemotherapy-induced colitis and possibly
alterations in the gastrointestinal microbiome as a conse-
quence of chemotherapeutic agents [29] might alter the
intestinal microbiological milieu, thereby enabling coloni-
zation and subsequent infection by toxin-producing C difﬁ-
cile. Similar associations have been seen in allogeneic HSCT
recipients, inwhom gut graft-versus-host diseasewas shown
to increase the risk for CDI [8]. Prospective studies are
needed to detail the association between damaged gut
integrity and development of CDI in the HSCT population.
One observation raised by these data is the possible
association between impaired host immune function and the
development of CDI. Several studies have noted an associa-
tion between older age and risk for CDI [30,31], which may
reﬂect defects in immunity related to age or the presence of
additional comorbid disease. The role of rituximab is
particularly intriguing in this analysis. It is well established
that defects in humoral immunity speciﬁc to CDI toxins may
play a role in the risk for primary as well as recurrent CDI
[32,33]. Impaired production of C difﬁcileespeciﬁc antibodies
is possible, increasing risk owing to the anti-CD20þ B cell
activity of rituximab. This possibility remains to be examined
in serologic studies in this population.
We evaluated the clinical characteristics and outcomes
among the 53 patients with CDI after auto-HSCT and found
that traditional markers of severe CDI, including fever
(37.7%), leukemoid reaction (1.9%), hypoalbuminemia (0%),
and the need for colectomy (0%), were uncommon. Serious
complications were not observed, and overall recurrence
rates were low (15%). Recently, new data have emerged
linking intestinal inﬂammation (as opposed to fecal
pathogen burden) with clinical outcomes after CDI [34].
The low percentage of complications in this patient
population may be related to decreased inﬂammation from
immunosuppression related to transplantation, rather than
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Contrary to the conventional wisdom that this patient pop-
ulation may have more severe disease related to immuno-
suppression, it is possible that these patients had attenuated
clinical presentations related to immunosuppression. This
observation has been noted in other immunosuppressed
patient populations [8,35]. Furthermore, we attempted to
account for the possibility that some patients may have
colonization with C difﬁcile, leading to overestimation of
rates, by using a deﬁnition of CDI that included clinical
symptoms of CDI, diarrheal stool, and detection of the
pathogen in stool. Although there is no standardized deﬁ-
nition for CDI in this patient population, this deﬁnition is
consistent with other reports in the ﬁeld [9,24,36,37].
This study has several limitations. First, the data were
collected retrospectively, and information on the duration
and severity of diarrhea was difﬁcult to obtain from the
medical record. Second, we might have underestimated the
numbers of recurrences and complications related to CDI
because of the relatively short time window in which
patients were closely monitored at the 2 centers before
returning to local medical care. Third, differences in CDI
testing practices across time and between centers might
have inﬂuenced annual rates. Finally, all studies have the
possibility of type I error, and thus our positive ﬁndings
should be conﬁrmed in other study populations of auto-
HSCT recipients.
In conclusion, this multicenter study is the ﬁrst to address
the key factors associated with the risk for CDI after auto-
HSCT. Overall rates of CDI did not differ in the 2 study
centers despite differences in NAP-1 endemicity. In this
population, treatment-related gastrointestinal mucosal
damage may predict the risk for CDI early after auto-HSCT.
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